
|Articles|September 1, 2003
Steroid is safe for treating conjunctivitis
Loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb Pharmaceuticals and Pharmos Corp.), the so-called "safe steroid" approved for treatment of seasonal allergic conjunctivitis, appears to be living up to its billing, according to several ophthalmologists who prescribe the drug for a range of ophthalmic allergies.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Neurotrophic keratitis outcomes improve with early, stage-based care
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5













































.png)


